

ACURA PHARMACEUTICALS, INC
Form 8-K
June 02, 2008

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934**

June 2, 2008
Date of Report (Date of earliest event reported)

ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

State of New York
(State of Other
Jurisdiction
of Incorporation)

1-10113
(Commission File
Number)

11-0853640
(I.R.S. Employer
Identification Number)

**616 N. North Court, Suite 120
Palatine, Illinois 60067**
(Address of principal executive offices) (Zip Code)

(847) 705-7709
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))

Item 8.01 Other Events

On June 2, 2008 Acura Pharmaceuticals, Inc. (“Acura”) issued the attached press release being furnished as Exhibit 99.1, announcing that clinical evaluation is now permitted under an active Investigational New Drug application for a certain opioid analgesic product candidate using Aversion® technology, previously licensed by Acura to King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals, Inc.

Item 9.01 Financial Statements and Exhibits

Exhibit Number

Description

99.1

Press Release of the Registrant dated June 2, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens

Peter A. Clemens
Senior Vice President & Chief Financial Officer

Date: June 2, 2008

EXHIBIT INDEX

Exhibit Number

Description

99.1

Press Release of the Registrant dated June 2, 2008.
